Bone Biologics Corp
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
BBLG$0.34+3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
Consolidated Statement of Stockholders’ Equity
For the Six Months ended June 30, 2024
(unaudited)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Equity | Equity | |
| Balance at December 31, 2023 | 534,238 | $534 | $83,814,785 | $(80,908,958) | $2,906,361 |
| Fair value of vested stock options | - | - | 52,681 | - | 52,681 |
| Options issued to settle accrued bonus | - | - | 77,400 | - | 77,400 |
| Proceeds from sale of common stock in public offering, net of offering costs of $490,227 | 344,938 | 345 | 1,503,994 | - | 1,504,339 |
| Exercise of pre-funded warrants | 137,313 | 137 | - | - | 137 |
| Net Loss | - | - | - | (865,970) | (865,970) |
| Balance at March 31, 2024 | 1,016,489 | 1,016 | 85,448,860 | (81,774,928) | 3,674,948 |
| Fair value of vested stock options | - | - | 17,443 | - | 17,443 |
| Exercise of pre-funded warrants | 299,000 | 299 | - | - | 299 |
| Net Loss | - | - | - | (783,733) | (783,733) |
| Balance at June 30, 2024 | 1,315,489 | $1,315 | $85,466,303 | $(82,558,661) | $2,908,957 |
Consolidated Statement of Stockholders’ Equity
For the Six Months ended June 30, 2023
(unaudited)
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Equity | Equity | |
| Balance at December 31, 2022 | 63,820 | $64 | $77,907,471 | $(71,960,227) | $5,947,308 |
| Fair value of vested stock options issued to employees and directors | - | - | 44,764 | - | 44,764 |
| Exercise of warrants | 5,837 | 6 | (6) | - | - |
| Extinguishment of warrant liability upon exercise of warrants | - | - | 490,226 | - | 490,226 |
| Net Loss | - | - | - | (3,709,899) | (3,709,899) |
| Balance at March 31, 2023 | 69,657 | $70 | $78,442,455 | $(75,670,126) | $2,772,399 |
| Fair value of vested stock options issued to employees and directors | - | - | 16,670 | - | 16,670 |
| Exercise of warrants | 4,938 | 5 | (5) | - | - |
| Extinguishment of warrant liability upon exercise of warrants | - | - | 220,798 | - | 220,798 |
| Proceeds from sale of common stock in public offering, net of offering costs $547,837 | 317,259 | 317 | 4,451,846 | - | 4,452,163 |
| Net Loss | - | - | - | (1,769,238) | (1,769,238) |
| Balance at June 30, 2023 | 391,854 | $392 | $83,131,764 | $(77,439,364) | $5,692,792 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.